肺癌组织病理学预后因素分析。

Frontiers of Radiation Therapy and Oncology Pub Date : 2010-01-01 Epub Date: 2009-11-24 DOI:10.1159/000262457
Annette Fisseler-Eckhoff
{"title":"肺癌组织病理学预后因素分析。","authors":"Annette Fisseler-Eckhoff","doi":"10.1159/000262457","DOIUrl":null,"url":null,"abstract":"<p><p>Carcinoma of the lung is the most common cause of cancer-related death in men and women. Prognosis correlates strongly with stage of disease at presentation and to some degree with the histological subtype of the tumor. Histological classifications of lung cancer were some what arbitrary and a matter of convenience. However, multiple lines of differentiation are often found within a single tumor, if it is sufficiently sampled. The new therapeutic approaches especially of non-small cell lung cancer place high demands on pathologists: a clear histological diagnosis with information on the predominant histological subtype is required, obtained by using additional immunohistochemical methods. Using molecular methods, predictive and prognostic factors for adjuvant and neoadjuvant therapies can be identified in tumor cells of small cell lung cancer and non-small cell lung cancer. Biological and molecular factors known in this regard include the epidermal growth factor family and its receptors, K-RAS mutations, neuroendocrine tumor differentiation, and nucleotide-excision-repair proteins (ERCC1 and RRM1). Thymidilate synthase is an interesting target for anticancer agents such as the antifolate pemetrexed. Given the aspect of individualized lung cancer therapy, the collective term small cell/non-small cell lung cancer introduced by the groups of Chuang in1984 and Thomas in 1993 can be regarded as no longer sufficient.</p>","PeriodicalId":55140,"journal":{"name":"Frontiers of Radiation Therapy and Oncology","volume":"42 ","pages":"1-14"},"PeriodicalIF":0.0000,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000262457","citationCount":"10","resultStr":"{\"title\":\"Prognostic factors in histopathology of lung cancer.\",\"authors\":\"Annette Fisseler-Eckhoff\",\"doi\":\"10.1159/000262457\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Carcinoma of the lung is the most common cause of cancer-related death in men and women. Prognosis correlates strongly with stage of disease at presentation and to some degree with the histological subtype of the tumor. Histological classifications of lung cancer were some what arbitrary and a matter of convenience. However, multiple lines of differentiation are often found within a single tumor, if it is sufficiently sampled. The new therapeutic approaches especially of non-small cell lung cancer place high demands on pathologists: a clear histological diagnosis with information on the predominant histological subtype is required, obtained by using additional immunohistochemical methods. Using molecular methods, predictive and prognostic factors for adjuvant and neoadjuvant therapies can be identified in tumor cells of small cell lung cancer and non-small cell lung cancer. Biological and molecular factors known in this regard include the epidermal growth factor family and its receptors, K-RAS mutations, neuroendocrine tumor differentiation, and nucleotide-excision-repair proteins (ERCC1 and RRM1). Thymidilate synthase is an interesting target for anticancer agents such as the antifolate pemetrexed. Given the aspect of individualized lung cancer therapy, the collective term small cell/non-small cell lung cancer introduced by the groups of Chuang in1984 and Thomas in 1993 can be regarded as no longer sufficient.</p>\",\"PeriodicalId\":55140,\"journal\":{\"name\":\"Frontiers of Radiation Therapy and Oncology\",\"volume\":\"42 \",\"pages\":\"1-14\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2010-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1159/000262457\",\"citationCount\":\"10\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers of Radiation Therapy and Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1159/000262457\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2009/11/24 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers of Radiation Therapy and Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000262457","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2009/11/24 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 10

摘要

肺癌是男性和女性癌症相关死亡的最常见原因。预后与疾病出现时的分期密切相关,在一定程度上与肿瘤的组织学亚型密切相关。肺癌的组织学分类有一些武断和方便的问题。然而,如果取样充分,在单个肿瘤中经常发现多个分化线。新的治疗方法,特别是非小细胞肺癌对病理学家提出了很高的要求:需要明确的组织学诊断,并通过使用额外的免疫组织化学方法获得主要组织学亚型的信息。利用分子方法,可以在小细胞肺癌和非小细胞肺癌的肿瘤细胞中确定辅助治疗和新辅助治疗的预测和预后因素。在这方面已知的生物和分子因素包括表皮生长因子家族及其受体、K-RAS突变、神经内分泌肿瘤分化和核苷酸切除修复蛋白(ERCC1和RRM1)。胸苷酸合成酶是抗叶酸药物培美曲塞等抗癌药物的一个有趣的靶点。从肺癌个体化治疗的角度来看,Chuang(1984)和Thomas(1993)等人提出的小细胞/非小细胞肺癌的统称已经不够了。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Prognostic factors in histopathology of lung cancer.

Carcinoma of the lung is the most common cause of cancer-related death in men and women. Prognosis correlates strongly with stage of disease at presentation and to some degree with the histological subtype of the tumor. Histological classifications of lung cancer were some what arbitrary and a matter of convenience. However, multiple lines of differentiation are often found within a single tumor, if it is sufficiently sampled. The new therapeutic approaches especially of non-small cell lung cancer place high demands on pathologists: a clear histological diagnosis with information on the predominant histological subtype is required, obtained by using additional immunohistochemical methods. Using molecular methods, predictive and prognostic factors for adjuvant and neoadjuvant therapies can be identified in tumor cells of small cell lung cancer and non-small cell lung cancer. Biological and molecular factors known in this regard include the epidermal growth factor family and its receptors, K-RAS mutations, neuroendocrine tumor differentiation, and nucleotide-excision-repair proteins (ERCC1 and RRM1). Thymidilate synthase is an interesting target for anticancer agents such as the antifolate pemetrexed. Given the aspect of individualized lung cancer therapy, the collective term small cell/non-small cell lung cancer introduced by the groups of Chuang in1984 and Thomas in 1993 can be regarded as no longer sufficient.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信